Stem cell-derived gametes: what to expect when expecting their clinical introduction
Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect-and investors to anticipate-the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including-but not limited to-safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.
Authors
- Susana M. Chuva de Sousa Lopes (ORCID: https://orcid.org/0000-0003-3866-2803)
- Simone Harmsen (ORCID: https://orcid.org/0000-0001-9745-0910)
- Ans M. M. van Pelt (ORCID: https://orcid.org/0000-0001-9155-548X)
- Seppe Segers (ORCID: https://orcid.org/0000-0001-8231-6487)
- Merel M. Spaander (ORCID: https://orcid.org/0000-0002-7137-5462)
- Guido de Wert (ORCID: https://orcid.org/0000-0002-0410-4902)
- Rosanne Edelenbosch
- Willy M. Baarends (ORCID: https://orcid.org/0000-0002-9179-850X)
- C.L. Mulder (ORCID: https://orcid.org/0000-0001-9160-7585)
- Ana M. Pereira Daoud (ORCID: https://orcid.org/0000-0002-0675-8133)
- Geert Hamer (ORCID: https://orcid.org/0000-0002-9583-6796)
- M.C. Ploem (ORCID: https://orcid.org/0000-0003-1466-0619)
- Ilse de Bruin (ORCID: https://orcid.org/0000-0001-7459-089X)
- Mathangi Lakshmipathi
- Nina Dartée
- Mariana Santos (ORCID: https://orcid.org/0000-0002-7836-1100)
Institutions
- Leiden University Medical Center (NL)
- Rathenau Instituut (NL)
- Novo Nordisk Foundation (DK)
- Ghent University Hospital (BE)
- Erasmus MC (NL)
- Foundation Center (US)
- University Medical Center (US)
- Ghent University (BE)
- Maastricht University (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Human Reproduction
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1093/humrep/deaf123
- Citations
- 4
- Primary Topic
- Pluripotent Stem Cells Research
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- ZonMw